ASX Announcement **9 September 2025**

Atomo Appoints Chair

SYDNEY Australia, 9 September 2025 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) advises that the Board has appointed Mr Patrick Cook, Non-Executive Director, as Independent Chair of the Board.

Mr Cook was appointed as a Non-Executive Director on the Board on 2 May 2025 as part of a recent restructure with Mr John Kelly stepping into the role of interim Chair to ensure continuity and stability in the leadership of the Company. Mr Cook's appointment will now allow Mr Kelly to focus entirely on his role of Managing Director.

Mr Cook is an experienced Non-Executive Director and Chair with over 35 years experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. Previously served as Non-Executive Director & Chair at Workplace Drug Testing Australasia Ltd and eWaste Connection Ltd. Currently a Committee Member at the University Animal Ethics Committee, QUT. Mr Cook is a Fellow of the Australian Institute of Company Directors and holds degrees in Applied Science and Marketing.

Mr Cook commented: "*I am honoured to be appointed as Chair of Atomo Diagnostics. I look forward to working with Atomo's Board of Directors towards fulfilling the company's strategic objectives in this exciting time for the organisation, as decentralised testing increasingly gains importance in the wider diagnostic market".*

~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

This announcement was authorised by the Board.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com